PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).
On September 29, 2026, uniQure's shares declined significantly after the Company reported updated 48-month data for ifezuntirgene inilparvovec, also known as AMT-130, its investigational gene therapy for Huntington’s disease.
On this news, uniQure's stock price was down more than 35% during intraday trading on September 29, 2026.
uniQure Investors: If you purchased uniQure stock and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or contact us to learn more about the investigation and your potential legal rights.
Learn more: https://kehoelawfirm.com/uniqure-securities-investigation-qure/
For a free, no-obligation legal evaluation, contact:
Michael Yarnoff, Esq. | (215) 792-6676, Ext. 804 | myarnoff@kehoelawfirm.com | info@kehoelawfirm.com
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a plaintiff-side class action law firm representing investors, consumers, and employees in securities fraud, corporate misconduct, antitrust, data breach, consumer fraud, employment, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases recovering more than $10 billion for investors.
Class action legal services are provided on a contingency-fee basis, subject to court approval of attorneys’ fees and expenses.
Attorney Advertising
